Head-To-Head Analysis: Mesoblast (NASDAQ:MESO) & SOPHiA GENETICS (NASDAQ:SOPH)

SOPHiA GENETICS (NASDAQ:SOPH) and Mesoblast (NASDAQ:MESO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.

Profitability

This table compares SOPHiA GENETICS and Mesoblast’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SOPHiA GENETICS	-110.71%	-55.06%	-38.33%
Mesoblast	N/A	N/A	N/A

Volatility and Risk

SOPHiA GENETICS has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, Mesoblast has a beta of 3.4, meaning that its share price is 240% more volatile than the S&P 500.

Institutional & Insider Ownership

31.6% of SOPHiA GENETICS shares are owned by institutional investors. Comparatively, 1.4% of Mesoblast shares are owned by institutional investors. 4.9% of SOPHiA GENETICS shares are owned by company insiders. Comparatively, 18.8% of Mesoblast shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares SOPHiA GENETICS and Mesoblast”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SOPHiA GENETICS	$65.17 million	3.34	-$78.98 million	($0.95)	-3.43
Mesoblast	$5.67 million	271.36	-$87.96 million	N/A	N/A

SOPHiA GENETICS has higher revenue and earnings than Mesoblast.

Analyst Recommendations

This is a summary of recent recommendations for SOPHiA GENETICS and Mesoblast, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SOPHiA GENETICS	0	1	3	0	2.75
Mesoblast	0	1	2	1	3.00

SOPHiA GENETICS presently has a consensus target price of $6.80, indicating a potential upside of 108.59%. Mesoblast has a consensus target price of $18.00, indicating a potential upside of 48.64%. Given SOPHiA GENETICS’s higher probable upside, equities research analysts clearly believe SOPHiA GENETICS is more favorable than Mesoblast.

Summary

Mesoblast beats SOPHiA GENETICS on 8 of the 13 factors compared between the two stocks.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.